Xencor, Inc. (XNCR)
| Market Cap | 1.32B |
| Revenue (ttm) | 326.64M |
| Net Income (ttm) | 108.71M |
| Shares Out | 59.54M |
| EPS (ttm) | 1.78 |
| PE Ratio | 12.50 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 215,311 |
| Open | 22.42 |
| Previous Close | 22.45 |
| Day's Range | 22.05 - 23.07 |
| 52-Week Range | 21.98 - 43.61 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 53.19 (+139.3%) |
| Earnings Date | May 5, 2022 |
About XNCR
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Its product candidates include Plamotamab, a tu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price forecast is 53.19, which is an increase of 139.27% from the latest price.
News
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on I...
Xencor (XNCR) Beats Q1 Earnings and Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 155.71% and 302.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor Reports First Quarter 2022 Financial Results
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseas...
3 Best Profitable Stocks to Buy Using Net Income Ratio
Xencor (XNCR), Encore Wire (WIRE) & Silvergate Capital (SI) have been selected as the top profitable picks with a high net income ratio.
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Researc...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune disea...
Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseas...
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with can...
Xencor (XNCR) to Report Q4 Results: Wall Street Expects Earnings Growth
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
MONROVIA, Calif., HONG KONG & BOSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment...
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annu...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
Xencor (XNCR) delivered earnings and revenue surprises of 8.00% and 11.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor: Q3 Earnings Insights
Xencor (NASDAQ:XNCR) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 S...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematol...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS' Multidisciplina...
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoim...
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoi...
Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.